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Discovery of Antivirulence Agents against Methicillin-Resistant
Staphylococcus aureus
Varandt Khodaverdian,a* Michelle Pesho,a Barbara Truitt,a* Lucy Bollinger,a* Parita Patel,a* Stanley Nithianantham,a* Guanping Yu,a*
Elizabeth Delaney,b Eckhard Jankowsky,b Menachem Shohama
Department of Biochemistry, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USAa; RNA Center, School of Medicine, Case Western Reserve
University, Cleveland, Ohio, USAb
Antivirulence agents inhibit the production of disease-causing virulence factors but are neither bacteriostatic nor bactericidal.
Antivirulence agents against methicillin-resistant Staphylococcus aureus (MRSA) strain USA300, the most widespread commu-
nity-associatedMRSA strain in the United States, were discovered by virtual screening against the response regulator AgrA,
which acts as a transcription factor for the expression of several of the most prominent S. aureus toxins and virulence factors
involved in pathogenesis. Virtual screening was followed by similarity searches in the databases of commercial vendors. The
small-molecule compounds discovered inhibit the production of the toxins alpha-hemolysin and phenol-soluble modulin  in a
dose-dependent manner without inhibiting bacterial growth. These antivirulence agents are small-molecule biaryl compounds
in which the aromatic rings either are fused or are separated by a short linker. One of these compounds is the FDA-approved
nonsteroidal anti-inflammatory drug diflunisal. This represents a new use for an old drug. Antivirulence agents might be useful
in prophylaxis and as adjuvants in antibiotic therapy for MRSA infections.
Staphylococcus aureus is themostwidespread bacterial pathogenin the developed world (1). One-third of the population
worldwide is thought to be colonized with S. aureus, usually in the
nose (2). Colonization is often harmless but sometimes becomes
pathogenic. The trigger for this transition is unknown but seems
to be associated with the penetration of S. aureus into broken skin,
bruises, and wounds, as well as sites of insertion of catheters and
other implants, and with host factors such as local or general im-
munosuppression (3). S. aureus causes a wide range of infections,
from skin and soft tissue infections to more-invasive infections,
such as pneumonia, endocarditis, meningitis, bacteremia, and
sepsis.
The increase in the rate of S. aureus infections has been
associated with hospitalization, affecting preferentially immu-
nocompromised individuals. Recently, however, such infec-
tions have increasingly occurred in the community, affecting
healthy individuals, such as athletes, students, and prisoners.
These community-associated infections are generally more vir-
ulent than hospital-associated infections (1).
Treatment of S. aureus infections is hampered by the steady
increase in resistance to antibiotics. Nowadays, more than two-
thirds of S. aureus infections are resistant to methicillin, a second-
generation -lactam antibiotic (2). Vancomycin, linezolid, and
daptomycin are the antibiotics of last resort against methicillin-
resistant Staphylococcus aureus (MRSA). Alarmingly, strains that
are resistant even to vancomycin have emerged recently (4). Thus,
the development of new antibacterial agents represents an urgent
unmet medical need.
Virulence factor production in S. aureus is regulated by a quo-
rum-sensing mechanism, predominantly under the control of the
accessory gene regulator (agr) operon (5). As shown in Fig. 1, the
autoinducing peptide (AIP) is the signalingmolecule coded for by
agrD and processed by agrB. Mature AIP is secreted to the cell
surface, where it binds to and activates the histidine kinase AgrC
on the same cell or on another cell. Subsequently, AgrC autophos-
phorylates and transfers its phosphoryl group to Asp 59 on the
N-terminal domain of the response regulator protein AgrA. Phos-
phorylated AgrA undergoes a conformational change to form a
dimer, which enables its C-terminal DNA-binding domains to
bind to promoter P2 to activate AIP transcription in an autocata-
lytic fashion. When the AIP concentration reaches a certain
threshold, AgrA also binds to the 10-fold-weaker binding pro-
moter P3, driving the expression of a series of toxins and virulence
factors in the post-exponential-growth phase (6).
The present work is based on the hypothesis that blocking
AgrA phosphorylation by use of small-molecule compounds
would inhibit toxin production. Top-scoring compounds identi-
fied through virtual screening against the phosphoryl-binding
pocket on AgrA were selected for in vitro screening of toxin sup-
pression in MRSA strain USA300 at the protein and RNA levels.
More such compounds were discovered by substructure searches
in online catalogs of chemical vendors. The best compounds in-
hibit rabbit blood hemolysis by 98% at a concentration of 10 g/
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ml. These compounds may provide the basis for the development
of antivirulence agents to combat MRSA.
MATERIALS AND METHODS
Homology modeling of the N-terminal regulatory domain of AgrA.
Since no crystal structure for the N-terminal regulatory domain of the S.
aureus response regulator AgrA is available, a model was built by homol-
ogy to the crystal structure of the regulatory domain of the sigma 54
transcriptional activator NtrC1 from Aquifex aeolicus (Protein Data Bank
[PDB] code 1NY5; resolution, 2.4 Å) (7). A model of residues 1 to 125 of
AgrA (UniprotKB code C5MZ29; S. aureus strain USA300_TCH959) was
built by the Swiss-Model server (8), followed by refinement with the CNS
program (9).
Virtual screening. The National Cancer Institute library of 90,000
small-molecule compounds was screened virtually using the Schrodinger
software suite on theHigh PerformanceComputingCluster at CaseWest-
ern Reserve University. The GLIDE program was used for docking the
compounds, one at a time, onto the phosphoryl-binding pocket of AgrA,
delineated by a 10 Å cube centered on the phosphoryl acceptor residue
Asp 59. The 107 top-scoring compounds were selected for in vitro testing.
Additional small-molecule compound candidates for in vitro testing were
identified by similarity and substructure searches on the online catalogs of
chemical vendors. A total of 250 compounds were acquired and were
subjected to in vitro testing.
ELISA for alpha-hemolysin (Hla).MRSA strainUSA300was cultured
overnight at 37°C in 1.5 ml Trypticase soy broth (TSB). The overnight
culture was diluted 1 to 100, and aliquots of 2mlwere added to designated
incubation tubes, followed by the addition of 40 l of 0.05 mg/ml, 0.5
mg/ml, or 2.5mg/ml of a compound in 100%dimethyl sulfoxide (DMSO)
to yield a final concentration of 1 g/ml, 10 g/ml, or 50 g/ml of the
compound, respectively. Fortymicroliters of 100%DMSOwas added to a
control incubation tube. The concentration of DMSO in the growth sam-
ples was 2%. The tubes were placed in a shaker and were incubated at
37°C for 6 h. Bacterial cultures were drawn into a syringe andwere filtered
through a 0.22-m filter. The filtrates were stored at80°C until use for
the enzyme-linked immunosorbent assay (ELISA).
Ninety-six-well microtiter plates (EIA [enzyme immunoassay]/RIA
[radioimmunoassay] plates; product no. 9017; Costar) containing 100
l/well of a polyclonal anti-Hla antibody (ab15948; Abcam) diluted
1:1,000 using phosphate-buffered saline (PBS), pH 7.2, were incubated
overnight at 4°C. The supernatant was then removed, and a bovine serum
albumin (BSA) block was conducted for 60 min at 4°C using 230 l of
10-mg/ml BSA in PBS (catalog no. P3688; Sigma). The supernatant was
removed, and the platewaswashed oncewith 230l of 0.05%Tween 20 in
PBS (catalog no. P3563; Sigma). One hundredmicroliters of the test sam-
ples (filtered supernatants of bacterial cultures, diluted 1:8 or 1:16 with
PBS) was added to the wells and was incubated for 1 h at room tempera-
ture with gentle rocking, followed by three washes with 230 l of 0.05%
Tween 20 in PBS. One hundred microliters of the anti-Hla antibody con-
jugated to horseradish peroxidase (ab15949; Abcam), diluted 1:1,000 in
10 mg/ml BSA in PBS (catalog no. P3688; Sigma), was then added to the
wells andwas incubated for 1 h with rocking. Threemore washes with 230
l of 0.05% Tween 20 in PBS were conducted, ensuring that no superna-
tant was left after the third wash. The plate was subsequently washed twice
with 230 l PBS, pH 7.2, and was allowed to drain on paper towels. One
hundred microliters of the substrate solution 3,3=,5,5=-tetramethylbenzi-
dine (TMB) (catalog no. T4444; Sigma) was added to each well, and the
plates were incubated at room temperature for 10 min, followed by the
addition of 100 l of stop reagent (catalog no. S5689; Sigma). The optical
density at 650 nm (OD650) was measured in a microplate reader, and the
percentage of inhibition was calculated relative to the level of growth with
the solvent DMSO.
In order to account for differences in bacterial growth in the presence
of the compounds, the number of CFU in each sample wasmeasured after
6 h of growth. Cultures were serially diluted, spread onto LB agar plates,
and incubated overnight at 37°C. The number of colonies on each plate
was counted. Hla inhibition data were normalized to the level of bacterial
growth with DMSO devoid of any potential inhibitor.
FIG 1 S. aureus agr operon for toxin production. The cyclic autoinducing peptide (AIP) is the signaling molecule coded for by agrD and processed by AgrB.
Mature AIP is secreted to the cell surface, where it binds to and activates the histidine kinase AgrC on the same cell or on a different cell. Subsequently, AgrC
autophosphorylates and transfers its phosphoryl group to Asp 59 on the N-terminal domain of the response regulator protein AgrA. Phosphorylated AgrA
undergoes a conformational change to form a dimer, which enables its C-terminal DNA-binding domains to bind to promoter P2 to activate AIP transcription
in an autocatalytic fashion. When the AIP concentration reaches a certain threshold, AgrA also binds to the 10-fold-weaker promoter P3, which drives the
transcription of RNAIII, amaster regulator of expression of a series of toxins and virulence factors in the post-exponential-growth phase (6). RNAIII encodes the
toxin delta-hemolysin (Hld). The drug discovery target in this work is the inhibition of phosphoryl transfer to AgrA, as indicated by the large shaded X at the top
center.
Khodaverdian et al.
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Rabbit blood hemolytic assay. The rabbit blood hemolytic assay is a
functional assay measuring the release of hemoglobin from erythrocytes
due to the hemolytic activity of Hla. Cultures of MRSA strain USA300
were grown at 37°C for 16 to 18 h with shaking to the post-exponential-
growth phase (OD600, 2.5; equivalent to 1  10
9 CFU/ml). Compounds
were added at various concentrations and were incubated for 6 h at 37°C.
Samples (100 l) of bacterial culture were filtered and were added to 900
l hemolysin buffer (0.145 M NaCl, 0.02 M CaCl2) and 25 l of defi-
brinated rabbit blood (Hemostat Laboratories, Dixon, CA). The solution
was incubated for 15 min at 37°C. Unlysed blood cells were pelleted by
centrifugation (5,500 g, room temperature, 1 min). The hemolytic ac-
tivity of the supernatant was determined bymeasuring the optical density
at 541 nm. Sterile culture medium served as the standard for 0% hemoly-
sis, and a bacterial culture supernatant devoid of any inhibitor (control)
was designated as the standard for 100% hemolysis. The percentage of
hemolysis inhibition was calculated by comparison with the control cul-
ture. Assays were performed in triplicate.
RNA isolation. Total RNA from MRSA strain USA300 was isolated
after 6 h of induction by using the RiboPure-Bacteria RNA isolation kit
(Ambion, Life Technologies) according to the manufacturer’s instruc-
tions with additional DNase I treatment. The RNA yield and purity were
assessed by measuring the ratio of UV absorbances at 260 and 280 nm as
described by the manufacturer. The integrity of the RNA was assessed on
a 1% denaturing agarose gel. High-integrity RNA had two clear bands
with no smearing, indicating no fragmentation of 23S and 16S rRNA.
Real-time RT-PCR. Quantitative reverse transcription-PCR (qRT-
PCR)was conducted onRNA isolates, and the levels of hla, psm, RNAIII,
and spa were assessed. The data were analyzed using the CT method;
samples induced with 2% DMSO were used as the control. The gene
corresponding to theDNA-binding proteinHupwas used as the reference
housekeeping gene.
Real-time RT-PCRs were conducted using a SYBR green mixture
(iScript One-Step RT-PCR kit with SYBR green; Bio-Rad). Each reaction
tube contained 12.5 l master mix, 0.5 l reverse transcriptase, 7 l
pooled forward and reverse primers, and 5 l (1 ng) total RNA. The
cycling program was carried out as recommended by the manufacturer
with an annealing and extension temperature of 56°C. Primer sequences
are listed in Table 1.
AgrA preparation. Plasmid pJR28, containing AgrA and an amino-
terminal hexahistidine tag, was a gift from Jonathan Reynolds and Si-
varamesh Wigneshweraraj of Imperial College London, London, United
Kingdom. AgrA was expressed in Escherichia coli by using the pET28b
expression vector as described previously (10). Briefly, cells were grown at
25°C, and the protein was expressed without isopropyl--D-thiogalacto-
pyranoside (IPTG) induction to prevent accumulation in inclusion bod-
ies. Cells were lysed by osmotic shock in 50mMHEPES (pH 7.3), 300mM
NaCl, 5% glycerol, and 3 mM -mercaptoethanol. The lysate was loaded
onto a preequilibrated nickel affinity column (HisTrap; GE Healthcare)
and was washed with lysis buffer plus 10 mM imidazole. The protein was
eluted with same buffer plus 250 mM imidazole, which migrated as a
single bandof 28 kDaon an SDS-PAGEgel. The identity of the proteinwas
confirmed by mass spectrometry (data not shown).
EMSA. The electrophoretic mobility shift assay (EMSA) wasmodified
from themethod described by Koenig et al. (6). The DNA sequences used
were the P3 promoter region (AATTTTTCTTAACTAGTCGTTTTTTAT
TCTTAACTGTAAATTTTT) and the negative control (CCTGGTTGTC
CTCGTCACTATGAAGAGCCTCACACACAAGGTCGTCGA) as given
in reference 6. Single strands were synthesized, purified by denaturing
polyacrylamide gel electrophoresis, and end labeled with 32P. The com-
plementary oligomers were then annealed, and the duplex was purified by
native polyacrylamide gel electrophoresis. To show AgrA binding, limit-
ing concentrations of DNA (1 nM) were allowed to equilibrate with vary-
ing concentrations of AgrA at 25°C for 30min in a 20-l solution initially
containing 50mM acetyl phosphate and a reaction buffer composed of 10
mMHEPES (pH 7.6), 1 mM EDTA, 2 mM dithiothreitol (DTT), 50 mM
KCl, 0.05%TritonX-100, and 5%glycerol. Because it became evident that
acetyl phosphate is not required for the formation of a specific AgrA-DNA
complex, acetyl phosphate was subsequently left out. EMSAs were per-
formedusing 4.5%native polyacrylamide gels in 0.5Tris-borate-EDTA.
Gels were run at 5 W at 4°C. The assay with diflunisal was performed
similarly, except that diflunisal was incubated with AgrA, DNA, and the
reaction buffer for 5min prior to the loading of the gel. Finished gels were
visualized by phosphorimaging (Storm 840 scanner; Amersham Biosci-
ences) and ImageQuant software.
RESULTS
AgrA model. The target protein for the discovery of small-mole-
cule compounds to inhibit S. aureus virulence factors in this work
is the regulatory domain of the response regulator AgrA. Crystal
structures of the C-terminal DNA-binding domain of AgrA by
itself and in complex with a cognate DNA fragment have been
reported (11, 12). However, no crystal structure of theN-terminal
regulatory domain of AgrA is available. Therefore, we resorted to
homology modeling. A model of the N-terminal regulatory do-
main of AgrA, residues 1 to 125, was built by homology to the
N-terminal domain of the transcriptional regulator NtrC1 from
Aquifex aeolicus (PDB code 1ZY2) (7). Although the degree of
sequence identity between the two protein domains is only 26%,
they share functional similarities, including the aspartic acid
phosphoryl receiver (Asp 59 in AgrA) embedded in the conserved
sequencemotif XDY,whereX is a an aliphatic or aromatic residue,
D is an aspartic acid, and Y is an aliphatic residue. This motif is
conserved in the activation domains of transcriptional regulators
of Gram-positive bacteria. Only the structure of the phosphoryl-
binding pocket, not the structure of the entire domain, is used for
the virtual screening of inhibitors. Therefore, this crystal structure
was deemed a valid basis for building a model of the phosphoryl-
binding pocket on the N-terminal domain of AgrA. The homolo-
gy-generated model of the N-terminal domain of AgrA displays a
distinct surface pocket centered on Asp 59, as shown in Fig. 2. The
dimensions of the pocket are roughly 10 by 10 by 10 Å. Residues
lining the binding pocket include Glu 7, Asp 8, Asp 9, Gln 12
(H-bonded toAsp 59), Leu 62, Val 87, and Lys 110 (salt-bridged to
Asp 59).
High-throughput virtual screening. The National Cancer In-
TABLE 1 Primers used in the qRT-PCR experiments
Gene Forward primer Reverse primer Reference
hup AGAAGCTGGTTCAGCAGTAGATG TACCTCAAAGTTACCGAAACCAA 29
hla ATGGATAGAAAAGCATCCAAACA TTTCCAATTTGTTGAAGTCCAAT 29
agrA CCTCGCAACTGATAATCCTTATG ACGAATTTCACTGCCTAATTTGA 29
RNAIII TTCACTGTGTCGATAATCCA TGATTTCAATGGCACAAGAT 30
psm TATCAAAAGCTTAATCGAACAATTC CCCCTTCAAATAAGATGTTCATATC 25
spa TTAAAGACGATCCTTCAGTGAGC TGTTGTTGTCTTCCTCTTTTGGT 29
Antivirulence Agents against MRSA
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stitute library of 90,000 small-molecule compounds was screened
virtually for the ability to block the phosphoryl-binding pocket of
AgrA. The 107 top-scoring compounds were acquired and were
tested for in vitro efficacy at inhibiting the formation of alpha-
hemolysin (Hla), the most important S. aureus toxin (13–16).
Inhibition of alpha-hemolysin (Hla) formation by potential
inhibitors. Activation of AgrA leads to increased Hla production.
Therefore, as an initialmeasure of AgrA inhibition,Hla levels were
measured by a sandwich ELISA. Seven of the top-scoring 107
compounds from virtual screening were found to inhibit Hla pro-
duction. Substructure searches were conducted at online catalogs
of chemical vendors in order to find additional compounds sim-
ilar to the initial positive hits. A total of 250 compounds were
assayed for inhibition of Hla production. Compounds that inhib-
ited bacterial growth were not examined further. The 11 most
active compounds, defined by the highest level of inhibition of
Hla, belong to two families, naphthalene derivatives and biaryl
compounds, as shown in Fig. 3. At 10 g/ml, four compounds
inhibited Hla formation by more than 70%; all the compounds
inhibited Hla in a dose-dependent manner (Table 2).
The ELISA inhibition data were corroborated by a hemolysis
assay. Hla creates holes in the membranes of various host cells,
such as immune system cells and erythrocytes. Interestingly, Hla
does not affect human red blood cells but does damage rabbit and
sheep erythrocytes. Rabbit erythrocytes were used for the hemo-
lysis assay. The amount of hemoglobin released from lysed red
blood cells was taken as ameasure ofHla production.Of the tested
compounds, all resulted inmarked decreases in the level of hemo-
lysis at both 1 g/ml and 10 g/ml, and all appeared to inhibit
hemolysis in a dose-dependent manner (Table 2). The highest
degree of inhibition was observed with compounds VI and IX,
which decreased hemolysis by more than 97% at a concentration
of 10 g/ml.
These compounds are neither bactericidal nor bacteriostatic.
None of these compounds inhibited growth at 1 or 10 g/ml.
Inhibition of transcription of agr-regulated toxin genes by
antivirulence compounds. To shed light on the mechanism of
Hla inhibition, RT-qPCR experiments were carried out in the
presence of selected antivirulence compounds. When MRSA was
incubated in the presence of 50 g/ml of the compounds, a
marked decrease in hla expressionwas observed, in particularwith
compounds IX, X, and XI (Fig. 4A). Furthermore, a decrease of at
least 2-fold in hla expression was observed for all the compounds
at 10 g/ml (except for compound V). Compound IX elicited the
most dramatic inhibition of theHla transcript, by a factor of about
1,000 at a concentration of 50 g/ml. This inhibition of hla is
consistent with the model of AgrA inhibition.
hla transcription is indirectly upregulated by phosphorylated
AgrA, whereas the regulator RNAIII and the leukolytic protein
phenol-solublemodulin (PSM) are directly upregulated by the
binding of phosphorylated AgrA to their respective promoters (5,
17). Therefore, RNAIII and psm expression is thought to be di-
rectly correlated to AgrA activation and, subsequently, inhibition.
WhenMRSA was incubated with select antivirulence compounds
at 50g/ml, psm expression decreased significantly (Fig. 4B). All
of the compounds investigated inhibited the transcription of Hla
and PSM in a dose-dependent manner, as shown in Fig. 4A and
B (except for compound XI).
RNAIII expressionwas onlymoderately inhibitedwhenMRSA
was incubated with compounds V, VII, and IX at 50 g/ml (Fig.
4C). Only compound IX decreased RNAIII expression at 10 g/
ml. In contrast to the downregulation of the toxins, expression of
the antiphagocytic surface protein Awas increased in the presence
of the compounds (Fig. 4D).
Inhibition of the binding of AgrA to promoter P3 by an anti-
virulence compound. In an effort to gain insight into the mecha-
nism of action of the antivirulence compounds, DNA-binding
experiments were carried out with purified AgrA and an oligonu-
cleotide corresponding to promoter P3, which drives the expres-
sion of virulence factors in S. aureus. As shown in Fig. 5, lane 2, a
strong band appears upon the addition of AgrA to the DNA frag-
ment, corresponding to the AgrA-P3 complex. The band corre-
sponding to this complex is not present when diflunisal (com-
pound IX) is added (Fig. 5, lane 3), indicating inhibition of specific
binding of AgrA to promoter P3 by the antivirulence compound.
Similar DNA-binding inhibition was observed with other com-
pounds (data not shown) and will be described in a follow-up
publication. Thus, the compounds inhibit the transcription of vir-
ulence factors by preventing the response regulator transcription
factor from binding to the promoter driving the expression of
virulence factors.
DISCUSSION
Antibiotics are currently the treatment of choice for MRSA infec-
tions, but increasing resistance to these agents, coupled with the
decline in the commercial development of new antibiotics, has
created an urgent need and a window of opportunity to introduce
new treatment options. TheWorldHealthOrganization has iden-
tified antimicrobial resistance as one of the three greatest threats
to human health. Antivirulence agents offer an alternative to an-
tibiotics. Will resistance to antivirulence agents develop? Viru-
lence factors empower the pathogen with chemical weapons,
which impair the ability of the host immune system to fight an
infection. Since the survival of bacteria is not threatened by anti-
virulence treatment, it is conceivable that resistance to these
FIG 2 Ribbon diagram of the homology-built model of the N-terminal do-
main of AgrA (AgrA_N). Residue Asp 59, shown in stick representation in a
pocket on the surface of the protein, is phosphorylated by the histidine kinase
AgrC, leading to activation of the C-terminal DNA-binding domain of AgrA,
which, in turn, triggers the induction of both the autoinducing peptide and
RNAIII, ultimately causing the transcription of a series of toxin genes. The
hypothesis is that blockage of the phosphohistidine pocket with a small mol-
ecule prevents toxin expression.
Khodaverdian et al.
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FIG 3 Structures of the most active compounds. Compound I, 4-hydroxybenzo[cd]indol-2(1H)-one; compound II, -oxynaphthoic acid; compound III,
2,3-difluoro-1-naphthoic acid; compound IV, 3-[3-(1,3-benzodioxol-5-yl)prop-2-enoyl]-2-hydroxy-cyclohepta-2,4,6-trien-1-one; compound V, 4-hydroxy-
3-methoxy-N-(naphthalen-1-ylmethylideneamino)benzamide; compound VI, 1-(5-ethyl-2,4-dihydroxyphenyl)-2-phenoxyethanone; compound VII, 3=-
fluoro-4=-hydroxy-4-biphenylcarboxylic acid; compound VIII, 5-benzoyl-4-hydroxy-2-methoxybenzenesulfonic acid; compound IX, 2=,4=-difluoro-4-hy-
droxybiphenyl-3-carboxylic acid (diflunisal); compound X, 3-phenyl salicylic acid; compound XI, 4,4=-fluorophenyl benzoic acid.
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agents will not significantly impede the efficacy of such drugs over
time. At present there are no data to support this assumption. One
might argue that antivirulence therapy, by suppressing pathogen-
host interactions, does create selective pressure, since it renders
the pathogen susceptible, once again, to innate immunity. The key
is that this selective pressure is present only in areas where innate
immunity is active. There is no selective pressure on the commen-
sal flora of nonvirulent bacteria or when the drug is released into
the environment (18). Thus, antivirulence therapy could help to
preserve the efficacy of conventional antibiotics.
There is currently no antivirulence agent in clinical use against
bacterial infections. However, data are available on animalmodels
FIG 5 Electrophoreticmobility shift assay of a 33P-labeled oligonucleotide corre-
sponding to the sequence promoter P3. Lane 1, DNA alone; lane 2, DNA plus 2
MAgrA; lane 3, DNA plus 2MAgrA plus 200Mdiflunisal (compound IX).
The strongband in lane2at ahighermolecularweight corresponds to theAgrA-P3
complex. This band is not present when diflunisal is added. The weak bands in
lanes 2 and 3may correspond to nonspecific AgrA-DNA complexes.
TABLE 2 Inhibitors of alpha-hemolysin formation and rabbit blood
hemolysis by MRSA USA300
Compound
% Alpha-hemolysin
inhibition as determined by
ELISAa at:
% Inhibition of hemolysis
of rabbit blood at:
1 g/ml 10 g/ml 1 g/ml 10 g/ml
I 28.0 4.4 65.0 2.5 NDb ND
II 21.3 5.2 76.0 1.2 42.0 2.8 69.9 6.1
III 20.8 3.5 28.3 3.4 ND ND
IV 40.2 5.2 73.6 2.2 ND ND
V 23.0 1.3 88.4 1.5 9.0 1.3 63.6 6.6
VI 55.2 5.8 76.3 11.2 9.2 0.7 97.9 9.3
VII 31.3 9.0 61.0 14.8 38.6 6.4 55.6 9.3
VIII 15.9 4.2 41.9 8.2 6.0 7.5 21.3 6.1
IX 33.0 3.6 62.3 1.8 63.0 1.9 97.7 4.2
X 49.4 4.6 53.0 5.9 34.3 6.9 84.7 6.7
XI 0.0 7.0 68.8 11.3 49.0 2.2 76.6 8.1
a ELISAs were carried out in 2% DMSO as the solvent. Control measurements with this
solvent were arbitrarily assigned values of 0% inhibition and 100% bacterial growth. All
other data were normalized to the control solvent data.
b ND, not determined.
FIG 4 Levels of transcription of hla, psm, and RNAIII in MRSA strain USA300 exposed to 10 g/ml (filled bars) or 50 g/ml (open bars) of compounds. No gene
expressionwas determined for compoundVI at 50g/ml because growth inhibition preventedRNA isolation. Values are averages for three separate experiments; error
bars indicate standard deviations. ***, P	 0.0005; **, P	 0.005; *, P	 0.05. (A) hla expression is displayed as log2 of relative gene expression. (B) psm expression is
displayed as log2 of relative gene expression. (C) RNAIII expression displayed as the fold change from the value withDMSO,whichwas set at 1. Values above 1 indicate
an increase in expression, while values below 1 signify inhibition of expression. (D) spa expression is displayed as log2 of relative gene expression.
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of S. aureus infections that shed light on the usefulness of antiviru-
lence agents for combating infections. Hla is an essential virulence
factor of S. aureus, and its level correlates with virulence in a
mouse model of S. aureus pneumonia (19). Monoclonal antibod-
ies against Hla provide protection against lethal S. aureus pneu-
monia in an experimentalmurinemodel and prevent human lung
cell injury in vitro (20). However, once the animals are infected,
treatment is effective when the antibodies are administered up to
8 h postinfection. Likewise, a-cyclodextrin derivative that blocks
the oligomeric assembly of Hla and inhibits its lytic function re-
duces the severity of MRSA infections in a murine model of S.
aureus pneumonia (21). As in the case of monoclonal anti-Hla
antibodies, treatment with the -cyclodextrin derivative at 10
mg/kg is of limited value postinfection, since the efficacy drops
when the compound is administered beyond 2 h postinfection.
However, active or passive immunization against Hla in a murine
model reduces the severity of skin and soft tissue infections caused
byMRSA strain USA300, the leading cause of community-associ-
ated MRSA infections in the United States (15).
In contrast to anti-Hla agents, which neutralize the action of a
single toxin, the compounds discovered in this work inhibit the
expression ofHla, Psm, and, to some extent, RNAIII. Alongwith
Hla, Psm is a key virulence factor in S. aureus infections (14). Hla
and Psm are toxins with complementary lytic activities against
the host. Whereas Psm is more efficacious in lysing neutrophils
(22), Hla is more lytic to erythrocytes in rabbits, mice, and sheep
but not in humans (23). The major contribution of Hla to patho-
genesis in humans is its interaction with the metalloprotease
ADAM10, which leads to disruption of epithelial barrier function
(13).
The agr operon is the most important operon for virulence
production in S. aureus. Knockout of the agr operon in MRSA
strain USA300 drastically reduces the size of abscesses in a rabbit
model of skin infections (14).
Inhibition of the agr system can, in principle, be achieved by
blocking any step along the pathway shown in Fig. 1. The receptor
histidine kinase AgrC was the target of a synthetic approach using
cyclic peptide mimics of the autoinducing peptide to inhibit re-
ceptor activation (17). Inhibitory antibodies have been shown to
cause agr quenching by sequestering the autoinducing peptide
(24). The target of agr inhibition in this workwas the transcription
factor AgrA, which controls the expression of all the virulence
factors under the control of the agr system. Hla is upregulated by
AgrA. In the presence of the antivirulence compounds described
in this work, there is a marked decrease in Hla production, as
shown by ELISA and rabbit blood hemolysis. Furthermore, a sig-
nificant decrease in the transcription of Hla was observed by RT-
qPCR. In addition, some of the compounds were shown to signif-
icantly inhibit the expression of PSM, a toxin directly
upregulated by phosphorylated AgrA in an RNAIII-independent
manner (25). Interestingly, the decrease in RNAIII expressionwas
not as large as that for Hla and PSM. This may be explained by
differential binding of AgrA to promoters in other operons, such
as sar, that trigger higher expression levels (26, 27). This finding is
corroborated by a report that induction ofHla transcription is not
coupled to higher concentrations of RNAIII (28). Whereas the
expression of the toxinsHla and PSM is inhibited, the expression
of the immune evasion protein A (Spa) is upregulated by the an-
tivirulence compounds. This finding is in accordance with a pre-
vious report of downregulation of protein A when agr is upregu-
lated (25). Whereas an increase in immune evasion is an
undesirable effect, it is counterbalanced by a marked decrease in
disease-causing toxins. Thus, the overall consequence of antiviru-
lence therapy may be a reduction in the severity of the infection.
Compound IX, diflunisal, is an FDA-approved nonsteroidal
anti-inflammatory drug. This represents a new use for an old
drug.Diflunisal inhibits the binding of AgrA to an oligonucleotide
corresponding to the DNA sequence of promoter P3, as shown in
Fig. 5. In principle, the formation of the specific protein-DNA
complex could be blocked by the binding of diflunisal either to
DNA or to AgrA. The latter is considered more likely. It is con-
ceivable that diflunisal causes a conformational change on AgrA
that impairs its DNA-binding capacity. Perhaps diflunisal pre-
vents the proper dimerization of AgrA required for specific pro-
moter binding (10).
The drug discovery target for this project was the phosphoryl-
binding pocket on the N-terminal domain of AgrA. However, the
binding of AgrA to promoter P3 does not require phosphorylation
(6), a finding corroborated in this work by the formation of a
specific AgrA-DNA complex in the absence of acetyl phosphate or
any other phosphate donor (Fig. 5). Thus, diflunisal may or may
not bind to the phosphoryl-binding pocket on AgrA. Recently a
ligand-binding pocket has been identified on the C-terminal
DNA-binding domain of AgrA (12). Thus, it is possible that
diflunisal binds to the C-terminal domain, or perhaps to both
domains, of AgrA. Localization of the diflunisal-binding site on
the surface of AgrAwill have to await a cocrystal structure of AgrA
and diflunisal.
The antivirulence compounds discovered in this work may
lead to the development of adjuvants to conventional antibiotic
therapy or perhaps to novel antimicrobials in monotherapy for
topical applications.
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